Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/dna-nanotechnology.md — the filesystem corpus, unchanged. Not an edit.
13.3 kB
Revision 1
Revision 2
lines 8–14 → 8–147 unchanged lines not shown
categories: ["nanomedicine", "genetics"]categories: ["nanomedicine", "genetics"]tags: ["nanomedicine", "dna origami", "self-assembly", "molecular machines", "drug delivery", "biosensing"]tags: ["nanomedicine", "dna origami", "self-assembly", "molecular machines", "drug delivery", "biosensing"]summary: "The use of DNA as a construction material rather than a carrier of genes, folding programmed sequences into nanoscale shapes, devices, and logic-gated containers."summary: "The use of DNA as a construction material rather than a carrier of genes, folding programmed sequences into nanoscale shapes, devices, and logic-gated containers."updated: "2026-07-27"updated: "2026-08-23"humanEvidence: "No DNA nanostructure has entered a human trial; the strongest results are logic-gated payload release on cultured human cells and thrombin-loaded tubes that slowed tumour growth in mice."humanEvidence: "No DNA nanostructure has entered a human trial; the strongest results are logic-gated payload release on cultured human cells and thrombin-loaded tubes that slowed tumour growth in mice."access: "Research use only: scaffolds and staple strands are ordinary laboratory reagents, and no DNA nanostructure is available as a medical product anywhere."access: "Research use only: scaffolds and staple strands are ordinary laboratory reagents, and no DNA nanostructure is available as a medical product anywhere."reversibility: "reversible"reversibility: "reversible"lines 93–98 → 93–10278 unchanged lines not shown
The obstacle to clinical translation is not design but pharmacology: an object made of nucleic acid must survive serum, avoid the liver, escape the endosome, and release cargo where intended, and the field has partial answers to each and a complete answer to none. The most likely first clinical entries are those where DNA's drawbacks matter least — vaccine and immunotherapy scaffolds, where immune recognition is the point, and topical or local applications, where circulation is not involved.The obstacle to clinical translation is not design but pharmacology: an object made of nucleic acid must survive serum, avoid the liver, escape the endosome, and release cargo where intended, and the field has partial answers to each and a complete answer to none. The most likely first clinical entries are those where DNA's drawbacks matter least — vaccine and immunotherapy scaffolds, where immune recognition is the point, and topical or local applications, where circulation is not involved. > [!caution] The leading candidate is a vaccine, not a carrier> The furthest-advanced construct is DoriVac, a square origami sheet that spaces CpG adjuvant and antigen at controlled distances. In 2026 it matched the approved mRNA vaccines on antibody and T-cell responses in mice and activated dendritic cells in a human lymph-node-on-chip, which is as close to a person as any DNA nanostructure has been.[^zeng2026]> Its mechanism is the TLR9 recognition of bacterial CpG described above — the property that disqualifies origami as a circulating carrier. A vaccine that works because the immune system notices it therefore says nothing about whether a DNA device can cross a bloodstream intact, which only a first human pharmacokinetic study would establish. Whether the addressability advantage ever justifies the fragility is the open question. A structure that positions two proteins exactly seven nanometres apart can do things no liposome can. As of 2026 nobody has shown that this buys enough in a patient to outweigh a material that dissolves in blood, and the [[crispr-cas9]] era has meanwhile demonstrated how much can be achieved with delivery vehicles that have no internal architecture at all.Whether the addressability advantage ever justifies the fragility is the open question. A structure that positions two proteins exactly seven nanometres apart can do things no liposome can. As of 2026 nobody has shown that this buys enough in a patient to outweigh a material that dissolves in blood, and the [[crispr-cas9]] era has meanwhile demonstrated how much can be achieved with delivery vehicles that have no internal architecture at all. ## See also## See alsolines 114–117 → 118–12215 unchanged lines not shown
[^li2018]: `paper` Li, S. et al. "A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo." *Nature Biotechnology*, 2018. {The therapeutic effect is in tumour-bearing mice; nothing comparable has been reported in people.}[^li2018]: `paper` Li, S. et al. "A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo." *Nature Biotechnology*, 2018. {The therapeutic effect is in tumour-bearing mice; nothing comparable has been reported in people.}[^ponnuswamy2017]: `paper` Ponnuswamy, N. et al. "Oligolysine-based coating protects DNA nanostructures from low-salt denaturation and nuclease degradation." *Nature Communications*, 2017.[^ponnuswamy2017]: `paper` Ponnuswamy, N. et al. "Oligolysine-based coating protects DNA nanostructures from low-salt denaturation and nuclease degradation." *Nature Communications*, 2017.[^veneziano2020]: `paper` Veneziano, R. et al. "Role of nanoscale antigen organization on B-cell activation probed using DNA origami." *Nature Nanotechnology*, 2020.[^veneziano2020]: `paper` Veneziano, R. et al. "Role of nanoscale antigen organization on B-cell activation probed using DNA origami." *Nature Nanotechnology*, 2020.[^zeng2026]: `paper` Zeng, Y. C. et al. "DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases." *Nature Biomedical Engineering*, 2026. {The head-to-head comparison with the mRNA vaccines is in mice; the human component is dendritic cells in a lymph-node-on-chip, not a dosed person.} removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
116 lines are the same in both revisions, and 100 of them are not shown. Neither revision here is necessarily the current article — read DNA nanotechnology for the text this wiki stands behind today.